“This MEDPAC report confirms exactly what we have been saying: rising drug prices are putting a colossal burden on America’s health care system and now total nearly 20 percent of health care spending. Without market-based solutions like transparency, competition, and value, we can only expect the problem to get worse.”
“The pharmaceutical industry’s habit of hiking prices on life-saving medications is appalling. Our campaign has been active in drawing attention to the price spikes on naloxone and we welcome this bipartisan effort to expose pharma’s price gouging tactics.”
We need to move toward market-based solutions to increase transparency, promote competition, and enhance value. For the millions of Americans living with chronic conditions – including allergies and arthritis, these solutions cannot come soon enough.
“Drug companies seem to be taking advantage of increased demand for Naloxone during this public health crisis by raising the price of a literally lifesaving medication,” said John Rother, executive director of the Campaign for Sustainable Rx Pricing.
“Annual prescription price hikes are driving the overall increase in health care costs and making health care less affordable for Americans. Today’s S&P report confirms what we’ve been saying — these increases in drug cost are unsustainable — and solutions to promote transparency, increase competition, and focus on value must be advanced,” said John Rother, executive director of the Campaign for Sustainable Rx Pricing (CSRxP).
Troubling numbers from the Centers for Disease Control and Prevention (CDC) this week show nearly 3.5 million Americans are currently living with hepatitis C – many of which are unaware of their infection. Luckily, this chronic illness is treatable, but at a staggering cost.
The Campaign for Sustainable Rx Pricing (CSRxP) kicked off the week with the introduction of its new policy platform aimed to curb skyrocketing prescription drug prices through increased transparency and competition which results in value. CSRxP’s solutions come at a critical time in the conversation about drug pricing, as this bipartisan issue garners unprecedented attention among policymakers, voters, and presidential candidates.
Drug prices in the United States are too high and continue to skyrocket. The unsustainable cost of prescription drugs not only puts pressure on the health care system but increasingly; patients, employers, and providers are paying prices that are too high.
Drug prices in the United States are too high and sharply rising prescription drug prices threaten the affordability of health care and the vitality of our entire economy. CSRxP has developed market-based reforms that restore a functioning market by increasing transparency, promoting competition and innovation, and that result in value.
“There is no silver bullet here. We need to balance affordability, access and innovation whether or not Medicare is directly involved in price negotiations. We can only strike that balance when the market has transparency and competition, and purchasers can pay for value.”